JPWO2022248478A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022248478A5
JPWO2022248478A5 JP2023571866A JP2023571866A JPWO2022248478A5 JP WO2022248478 A5 JPWO2022248478 A5 JP WO2022248478A5 JP 2023571866 A JP2023571866 A JP 2023571866A JP 2023571866 A JP2023571866 A JP 2023571866A JP WO2022248478 A5 JPWO2022248478 A5 JP WO2022248478A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521105A5 (https=
JP2024521105A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/064061 external-priority patent/WO2022248478A1/en
Publication of JP2024521105A publication Critical patent/JP2024521105A/ja
Publication of JP2024521105A5 publication Critical patent/JP2024521105A5/ja
Publication of JPWO2022248478A5 publication Critical patent/JPWO2022248478A5/ja
Pending legal-status Critical Current

Links

JP2023571866A 2021-05-24 2022-05-24 肺癌の処置用組成物及び方法 Pending JP2024521105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192217P 2021-05-24 2021-05-24
US63/192,217 2021-05-24
PCT/EP2022/064061 WO2022248478A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Publications (3)

Publication Number Publication Date
JP2024521105A JP2024521105A (ja) 2024-05-28
JP2024521105A5 JP2024521105A5 (https=) 2025-06-03
JPWO2022248478A5 true JPWO2022248478A5 (https=) 2025-06-03

Family

ID=82100132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571866A Pending JP2024521105A (ja) 2021-05-24 2022-05-24 肺癌の処置用組成物及び方法

Country Status (11)

Country Link
US (1) US20240254235A1 (https=)
EP (1) EP4347038A1 (https=)
JP (1) JP2024521105A (https=)
KR (1) KR20240012413A (https=)
CN (1) CN117425493A (https=)
AU (1) AU2022281992A1 (https=)
BR (1) BR112023023833A2 (https=)
CA (1) CA3219960A1 (https=)
IL (1) IL308530A (https=)
TW (1) TW202313107A (https=)
WO (1) WO2022248478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936347A (zh) * 2023-04-14 2025-11-11 阿斯利康(瑞典)有限公司 非小细胞肺癌的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US20190276543A1 (en) * 2018-03-08 2019-09-12 Astrazeneca Pharmaceuticals Lp Compositions and methods for treating late stage lung cancer
BR112022022304A2 (pt) * 2020-05-04 2022-12-20 Merck Sharp & Dohme Llc Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp

Similar Documents

Publication Publication Date Title
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
JP2003531129A5 (https=)
Kouroussis et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
JP2021518394A5 (https=)
WO2016180958A1 (en) Treatment for multiple myeloma (mm)
JP2019532970A5 (https=)
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN115052628A (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2021529777A5 (https=)
JP2021523096A5 (https=)
JPWO2021224499A5 (https=)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JPWO2022248478A5 (https=)
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
EP4583880A1 (en) Compositions and methods for treating advanced solid tumors
CN120752053A (zh) 含抗tim-3抗体的药物组合
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合
JPWO2020018789A5 (https=)
JPWO2021043955A5 (https=)
JPWO2022002153A5 (https=)
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
JPWO2023056461A5 (https=)
IL311796A (en) Anti-galectin-9 antibodies and their therapeutic uses